Loading...
  • autologous
  • The promising results published in recent years, both with autologous and in allogeneic cells, highlight a need for greater understanding of the basic principles of this new route and for clarification of the current state of the topic. (intechopen.com)
  • alloSCT
  • Approximately 12-26 patients with relapsed MDS, AML, or mature B cell (B-NHL, cHL) malignancies that have relapsed following alloSCT will be enrolled on this trial. (clinicaltrials.gov)
  • To determine the tolerability of pembrolizumab treatment in the setting of relapsed myeloid malignancies and mature B cell lymphomas following alloSCT. (clinicaltrials.gov)
  • To determine the duration of response (DOR) of patients treated with pembrolizumab in the setting of relapsed myeloid malignancies and mature B cell lymphomas following alloSCT. (clinicaltrials.gov)
  • To determine the overall response rate (ORR) of patients treated with pembrolizumab in the setting of relapsed myeloid malignancies and mature B cell lymphomas following alloSCT, stratified by disease type. (clinicaltrials.gov)
  • malignancy
  • Lung transplantation is rarely performed in this setting due to concomitant extrapulmonary morbidity, excessive immunosuppression and concerns about recurring malignancy being considered contraindications. (ersjournals.com)
  • therapeutic
  • They are able to generate cell lines derived from any of the three embryonic germ layers (ectoderm, mesoderm and endoderm), giving them great therapeutic potential. (intechopen.com)
  • However, based on the so‐called phenomenon of cellular plasticity, in some instances, they can differentiate into cell populations different to those of their embryonic origin, providing many therapeutic options [ 16 ]. (intechopen.com)
  • Allogeneic stem cell transplantation is a therapeutic approach with known curative potential for patients with MDS that allows the achievement of long-term disease control. (dovepress.com)
  • A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. (jcancer.org)
  • investigators
  • The EpiStem investigators form a European Consortium of hematologists, infectious disease specialists, virologists, immunologists and blood/tissue bank specialists from France, Germany, Spain, the Netherlands and the United Kingdom who collaborate with clinicians globally to enroll patients to study blood and tissue samples before and after the stem cell transplantation. (natap.org)
  • therapy
  • In this scenario, cell therapy is envisaged as an effective alternative to surgery. (intechopen.com)
  • The promising preclinical and clinical data that we review below suggest that cell therapy could represent a major advance in the clinical management of this difficult problem. (intechopen.com)
  • It is as a result of these inadequacies in current treatment strategies that cell therapy has arisen as a complementary option [ 14 ]. (intechopen.com)
  • Myeloid
  • Myeloid or granulocytic sarcoma (GS) is a tumoral lesion consisting of immature granulocytic cells. (hindawi.com)
  • The antibody portion of Gemtuzumab binds specifically to the CD33 antigen, a sialic acid-dependent adhesion protein expressed on the surface of leukemic blasts, normal and leukemic myeloid colony-forming cells, including leukemic clonogenic precursors, but excluding pluripotent hematopoietic stem cells and nonhematopoietic cells. (clinicaltrials.gov)
  • This results in formation of a complex that is internalized, upon which the calicheamicin derivative is released within the lysosomes of the myeloid cell. (clinicaltrials.gov)
  • Over 80% of AML patients possess myeloid blast cells with CD33 surface antigen expression. (clinicaltrials.gov)
  • recipient
  • Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient. (clinicaltrials.gov)
  • The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). (clinicaltrials.gov)
  • Randomization was carried out centrally at the International Institute for Drug Development (id2), Brussels, Belgium, and used the minimization method to allocate donor and recipient to allogeneic BMT or PBPCT. (clinicaltrials.gov)